IP Library Granted Patent US 9,592,256
Granted Patent B2
US 9,592,256 · App. 14/193,664 · Granted Mar 14, 2017

Compositions and methods for tissue repair with extracellular matrices

Inventors: Karen Christman (San Diego, CA); Jessica DeQuach (La Jolla, CA)
Assignee: The Regents of the University of California
A61K35/34A61K9/0024A61L27/34A61L27/3633A61L27/38A61L27/52A61L27/54A61L27/58A61L2400/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,592,256
App. No.
14/193,664
Granted
Mar 14, 2017
Kind
B2
Abstract

Described herein are compositions comprising decellularized extracellular matrix derived from skeletal muscle or other suitable tissue, and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, damage, ischemic, ulcer cells, tissues or organs in a subject preferably a human, with diseases, such as PAD and CLI, using a decellularized extracellular matrix of the invention are provided. Methods of preparing culture surfaces and culturing cells with absorbed decellularized extracellular matrix are provided.

Claims (17)

1. A method for treating peripheral artery disease comprising injecting or implanting in a subject with peripheral artery disease an effective amount of a composition comprising decellularized extracellular matrix derived from skeletal muscle tissue, wherein the composition does not contain hepatocyte growth factor.

2. The method of claim 1 , wherein said composition is coated on an implant.

3. The method of claim 1 , wherein said composition is delivered as a liquid or a powder.

4. The method of claim 3 , wherein said composition transitions to a gel form after delivery.

5. The method of claim 1 , wherein said composition degrades within one to three months following injection or implantation.

6. The method of claim 1 , wherein injection or implantation of said composition repairs damage to skeletal muscle tissue sustained by said subject.

7. The method of claim 1 , wherein injection or implantation of said composition repairs damage caused by ischemia in said subject.

8. The method of claim 1 , wherein said effective amount is an amount that increases blood flow, increases muscle mass, or induces new vascular formation in the area of the injection or implantation of the subject.

9. The method of claim 1 , wherein the effective amount is effective for treating at least one of the symptoms selected from the group consisting of ulcers, trauma wounds, draining wounds, inflammation, Buerger disease, atherosclerosis obliterans, thromboangiitis obliterans, and gangrene associated with peripheral artery disease.

10. A method comprising injecting or implanting in a subject with critical limb ischemia an effective amount of a composition comprising decellularized extracellular matrix derived from skeletal muscle tissue, wherein the composition does not contain hepatocyte growth factor.

11. The method of claim 10 , where said composition is coated on an implant.

12. The method of claim 10 , wherein said composition is delivered as a liquid or a powder.

13. The method of claim 12 , wherein said composition degrades within one to three months following injection or implantation.

14. The method of claim 10 , wherein injection or implantation of said composition repairs skeletal muscle tissue damage caused by ischemia in said subject.

15. The method of claim 10 , wherein said composition transitions to a gel form after delivery.

16. The method of claim 10 , wherein said effective amount is an amount that increases blood flow, increases muscle mass, or induces new vascular formation in the area of the injection or implantation of the treated subject.

17. The method of claim 10 , wherein the effective amount is effective for treating at least one of the symptoms selected from the group consisting of ulcers, trauma wounds, draining wounds, inflammation, Buerger disease, atherosclerosis obliterans, thromboangiitis obliterans, and gangrene associated with peripheral artery disease.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 31, 2014
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 032568/0486 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2014
From: CHRISTMAN, KAREN; DEQUACH, JESSICA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 032325/0059 →
Continuity (3)
Continuation PCTUS2012054058 · Sep 7, 2012
Provisional Application 61531931 · Sep 7, 2011
Related Publication 20140178450A1 · Jun 26, 2014